Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.~* Premature or scheduled termination of standard therapy~* Progressive disease as clinically assessed by the investigator~* Max. tumour lesion ≤ 5 cm~* Adequate organ function~* Ability of patient to understand character and individual consequences of clinical trial~* Age ≥ 18 years~* Written informed consent must be available before any study specific procedure is performed~Exclusion Criteria:~* Patients with severe heart diseases~* Clinical significant ischemic disease during the last 4 weeks before Visit 1~* Severe lung disease~* Symptomatic peritoneal carcinomatosis~* Symptomatic pleural or pericardial effusion~* Serious uncontrolled acute infections less than 3 weeks before Visit 1~* Known dependency on alcohol or other drugs~* Patients requiring corticoids in doses above the Cushing threshold~* Known liver fibrosis or liver cirrhosis~* Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator~* Female patient who is pregnant or breast feeding~* Participation in another clinical trial or observation period, respectively, during the last 4 weeks prior to the first IMP dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).